title: Tamoxifen therapy in kidney-transplant patients presenting with severe encapsulating peritoneal sclerosis after treatment for acute humoral rejection.
abstract: OBJECTIVE
  Encapsulating peritoneal sclerosis is a rare but serious complication in patients undergoing peritoneal dialysis. Its mortality rate is approximately 30%, despite treatment with total parenteral nutrition, surgery, tamoxifen, or immunosuppressants.
  
  
  METHODS
  Of 991 kidney transplants performed at our institution over 9 years, 50 patients were treated for chronic peritoneal dialysis at the time of transplant.
  
  
  RESULTS
  Two cases of encapsulating, peritoneal sclerosis occurred in patients receiving pretransplant peritoneal dialysis. Both had received intensive posttransplant treatment for acute humoral rejection. Encapsulating peritoneal sclerosis occurred at 3 months and 4 months after the transplant. Both presented with intestinal pain and gut obstruction. They were given total parenteral nutrition plus tamoxifen (20 mg/d) for 3 months. Outcomes were favorable for 1, though there was no improvement for the second patient, who was then also given sirolimus. He died later from multiorgan failure secondary to digestive-related sepsis, and encapsulating, peritoneal, sclerosis-related symptoms.
  
  
  CONCLUSIONS
  When encapsulating, peritoneal sclerosis occurs after kidney transplant, tamoxifen therapy could be implemented.
authors.affiliation: Department of Nephrology, Dialysis and Organ Transplantation, CHU Rangueil, Toulouse, France.
authors.forename: Abdellatif Ould
authors.initials: AO
authors.lastname: Mohamed
authors.forename: Nassim
authors.initials: N
authors.lastname: Kamar
authors.forename: Marie-Béatrice
authors.initials: MB
authors.lastname: Nogier
authors.forename: Laure
authors.initials: L
authors.lastname: Esposito
authors.forename: Jean Pierre
authors.initials: JP
authors.lastname: Duffas
authors.forename: Lionel
authors.initials: L
authors.lastname: Rostaing
mesh_terms: D000208:Acute Disease; D000328:Adult; D003131:Combined Modality Therapy; D004359:Drug Therapy, Combination; D017809:Fatal Outcome; D006084:Graft Rejection / Q000276:immunology / Q000628:therapy*; D006801:Humans; D056724:Immunity, Humoral / Q000187:drug effects*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D009102:Multiple Organ Failure / Q000209:etiology; D010289:Parenteral Nutrition, Total; D010531:Peritoneal Dialysis, Continuous Ambulatory / Q000009:adverse effects*; D056627:Peritoneal Fibrosis / Q000188:drug therapy* / Q000209:etiology; D010956:Plasmapheresis; D012720:Severity of Illness Index; D013629:Tamoxifen / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents; D013629:Tamoxifen